WallStreetZenWallStreetZen

NYSEMKT: MTNB
Matinas Biopharma Holdings Inc Stock

$0.13+0.00 (+0%)
Updated Sep 29, 2023
MTNB Price
$0.13
Fair Value Price
N/A
Market Cap
$28.24M
52 Week Low
$0.11
52 Week High
$0.89
P/E
-1.18x
P/B
1.01x
P/S
18.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.28M
Earnings
-$20.67M
Gross Margin
100%
Operating Margin
-482.47%
Profit Margin
-482.5%
Debt to Equity
0.22
Operating Cash Flow
-$16M
Beta
1
Next Earnings
Oct 31, 2023
Ex-Dividend
N/A
Next Dividend
N/A

MTNB Overview

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company is headquartered in Bedminster, New Jersey and currently employs 15 full-time employees. The firm focuses on identifying and developing novel pharmaceutical products. The firm's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The firm's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The firm's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MTNB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MTNB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTNB is good value based on its book value relative to its share price (1.01x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
MTNB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MTNB due diligence checks available for Premium users.

Be the first to know about important MTNB news, forecast changes, insider trades & much more!

Valuation

MTNB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.18x
Industry
13.67x
Market
12.37x

MTNB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
5.09x
MTNB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MTNB's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.1M
Profit Margin
0%
MTNB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MTNB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$34.0M
Liabilities
$6.2M
Debt to equity
0.22
MTNB's short-term assets ($24.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTNB's short-term assets ($24.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTNB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MTNB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.2M
Investing
$6.2M
Financing
-$1.0k
MTNB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MTNB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MTNB$28.24M0.00%-1.18x1.01x
ELEV$28.10M-1.92%-0.19x0.39x
ABIO$28.96M0.00%-4.67x0.74x
COEP$29.16M+8.41%-0.48x11.71x
ENLV$29.37M+5.33%-1.08x0.66x

Matinas Biopharma Holdings Stock FAQ

What is Matinas Biopharma Holdings's quote symbol?

(NYSEMKT: MTNB) Matinas Biopharma Holdings trades on the NYSEMKT under the ticker symbol MTNB. Matinas Biopharma Holdings stock quotes can also be displayed as NYSEMKT: MTNB.

If you're new to stock investing, here's how to buy Matinas Biopharma Holdings stock.

What is the 52 week high and low for Matinas Biopharma Holdings (NYSEMKT: MTNB)?

(NYSEMKT: MTNB) Matinas Biopharma Holdings's 52-week high was $0.89, and its 52-week low was $0.11. It is currently -85.39% from its 52-week high and 18.18% from its 52-week low.

How much is Matinas Biopharma Holdings stock worth today?

(NYSEMKT: MTNB) Matinas Biopharma Holdings currently has 217,264,526 outstanding shares. With Matinas Biopharma Holdings stock trading at $0.13 per share, the total value of Matinas Biopharma Holdings stock (market capitalization) is $28.24M.

Matinas Biopharma Holdings stock was originally listed at a price of $3.85 in Mar 2, 2017. If you had invested in Matinas Biopharma Holdings stock at $3.85, your return over the last 6 years would have been -96.62%, for an annualized return of -43.15% (not including any dividends or dividend reinvestments).

How much is Matinas Biopharma Holdings's stock price per share?

(NYSEMKT: MTNB) Matinas Biopharma Holdings stock price per share is $0.13 today (as of Sep 29, 2023).

What is Matinas Biopharma Holdings's Market Cap?

(NYSEMKT: MTNB) Matinas Biopharma Holdings's market cap is $28.24M, as of Sep 30, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Matinas Biopharma Holdings's market cap is calculated by multiplying MTNB's current stock price of $0.13 by MTNB's total outstanding shares of 217,264,526.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.